ALDX Insider Trading Activity and SEC Form 4 Filings
ALDX insider trading summary
Over the past 12 months, insiders at Aldeyra Therapeutics, Inc. (ALDX) reported 1 open-market purchase worth $98K by 1 insider and no sales on SEC Form 4. Net insider buying was $98K.
Latest ALDX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 19, 2026 | Richard Douglas | Insider | Buy | $98K (70,000 @ $1.40) |
| Aug 13, 2025 | Michael Alfieri | Principal Financial Officer | Buy | $13K (2,500 @ $5.30) |
| Aug 11, 2025 | Stephen Machatha | Chief Development Officer | Sell | $114K (22,073 @ $5.15) |
| Apr 3, 2025 | Perceptive Advisors LLC | 10% Owner | Sell | $4.8M (3,400,000 @ $1.42) |
| Apr 3, 2025 | Joseph Edelman | 10% Owner | Sell | $4.8M (3,400,000 @ $1.42) |
| Apr 3, 2025 | Perceptive Life Sciences Master Fund Ltd | 10% Owner | Sell | $4.8M (3,400,000 @ $1.42) |
| Aug 12, 2024 | Stephen Machatha | Chief Development Officer | Sell | $76K (16,041 @ $4.74) |
| Aug 12, 2024 | Bruce Greenberg | See Remarks | Sell | $51K (10,834 @ $4.74) |
| Apr 5, 2024 | Perceptive Advisors LLC | 10% Owner | Buy | $179K (37,712 @ $4.74) |
| Apr 5, 2024 | Joseph Edelman | 10% Owner | Buy | $179K (37,712 @ $4.74) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.